Pfizer Affirms Patents and throws off Challenge from Teva

The U.S. Court of Appeals of the Federal Circuit (FAFC) reaffirmed two out of three of Pfizer’s patents for the arthritis pain drug Celebrex on Friday. Teva will now have to wait until May 2014 to market their generic version of the drug.

Celebrex has shown clear benefits for arthritis sufferers but has also been alleged to risk heart attacks and strokes.

This entry was posted on Saturday, March 8th, 2008 at 8:38 pm and is filed under drugs, Intellectual Property, pharmaceuticals, pharmaceuticals and Biotechnology, Teva. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply Cancel reply

Enter your comment here...

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account. ( Log Out / Change )

You are commenting using your Twitter account. ( Log Out / Change )

You are commenting using your Facebook account. ( Log Out / Change )

Cancel

Connecting to %s

The IP Factor